Philippe Aftimos, MD · @aftimosp · X·· 2 天前评分70
正文 · 机器翻译
@BarbaraPistill2 关于抗 HER2 ADC 摘要的一些要点
🔹采用相同靶点、连接子及载荷类别的 3 种 ADC 试验
🔹在 TALENT 研究中，较低的 pCR 率与 NACT 以及 HR+/ HER2- EBC 中其他 ADC 的 pCR 率相当
@myESMO #ESMOAmbassadors
#ESMO26
1/2
449 浏览 · 8 赞 · 5 转发 · 1 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org帖内回复
- Philippe Aftimos, MD @aftimosp
🔹 Move towards the development and implementation of quantitative assessment of targets 🔹 Future clinical trial designs incorporating biomarker testing in early breast cancer and investigating sequential strategies in MBC @myESMO #ESMOAmbassadors #ESMO26 2/2
来源：Philippe Aftimos, MD · x.com